Ironwood Pharma (IRWD) Misses Q2 EPS by 4c, Revenues Miss; Offers 2018 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update
August 6, 2018 8:00 AM EDTSecond quarter revenue increased 25% year-over-year to $81 million, driven primarily by LINZESS® (linaclotide) U.S. net sales of $192 million and commercial margin of 60%
Terminating licensing agreement with AstraZeneca for U.S. lesinurad franchise
Initiated Phase III programs with IW-3718 and linaclotide and advanced four Phase II trials with lead sGC stimulators, praliciguat and olinciguat
On track to complete separation of Ironwood into two independent, publicly traded companies in first half 2019
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
